GLP-1 Drugs: The Complete 2026 List

There are eight FDA-approved GLP-1 receptor agonists on the US market in 2026, plus compounded semaglutide and tirzepatide through telehealth. This page lists them all with indication, dosing, cost, and key trial outcomes.

Last updated May 1, 2026.

Quick Reference Table

Detailed Cards

By Molecule: What Each Active Ingredient Does

Semaglutide

The most prescribed GLP-1 in the US. Brand names Ozempic (T2D), Wegovy (weight), Rybelsus (T2D, oral). Average weight loss ~15% in STEP-1. Full detail on semaglutide.

Tirzepatide

Dual GIP/GLP-1 agonist. Brand names Mounjaro (T2D), Zepbound (weight, OSA). Average weight loss ~22% at top dose in SURMOUNT-1. Full detail on tirzepatide.

Liraglutide

First once-daily injectable GLP-1. Brand names Victoza (T2D) and Saxenda (weight). Older, less potent than weekly options. Saxenda is FDA-approved for adolescents aged 12+.

Dulaglutide

Weekly injectable for type 2 diabetes (Trulicity). Cardiovascular benefit demonstrated in REWIND trial. Often well-tolerated.

Exenatide

First GLP-1 RA, approved 2005. Two formulations: twice-daily Byetta and weekly Bydureon. Largely replaced by newer drugs.

Lixisenatide

Daily injectable (Adlyxin). Limited use in the US; more common internationally.

FDA Approval Timeline

• 2005 — Exenatide (Byetta)
• 2010 — Liraglutide (Victoza)
• 2012 — Exenatide extended-release (Bydureon)
• 2014 — Albiglutide (Tanzeum; later discontinued)
• 2014 — Liraglutide 3 mg (Saxenda) for obesity
• 2014 — Dulaglutide (Trulicity)
• 2016 — Lixisenatide (Adlyxin)
• 2017 — Semaglutide injection (Ozempic)
• 2019 — Oral semaglutide (Rybelsus)
• 2021 — Semaglutide 2.4 mg (Wegovy) for obesity
• 2022 — Tirzepatide (Mounjaro) for T2D
• 2023 — Tirzepatide (Zepbound) for obesity
• 2024 — Zepbound expanded for OSA in obesity

By Indication

FDA-Approved for Weight Management

• Wegovy (semaglutide 2.4 mg)
• Zepbound (tirzepatide)
• Saxenda (liraglutide 3 mg)

FDA-Approved for Type 2 Diabetes

• Ozempic (semaglutide)
• Rybelsus (semaglutide oral)
• Mounjaro (tirzepatide)
• Trulicity (dulaglutide)
• Victoza (liraglutide)
• Byetta / Bydureon (exenatide)
• Adlyxin (lixisenatide)

Other FDA-Approved Indications

• Wegovy — Cardiovascular risk reduction in established CV disease
• Zepbound — Obstructive sleep apnea in obesity
• Ozempic — Cardiovascular risk reduction in T2D
• Trulicity — Cardiovascular risk reduction in T2D
• Saxenda — Weight management in adolescents (12+)

Pipeline: What's Coming Next

Several late-stage GLP-1 and combination drugs are in clinical trials in 2026:

• Retatrutide (Lilly) — triple agonist (GIP/GLP-1/glucagon). Phase 3 trials reported the largest weight loss yet (~24%).
• Orforglipron (Lilly) — oral small-molecule GLP-1 agonist, easier to manufacture and ship than peptides.
• CagriSema (Novo Nordisk) — combination of cagrilintide and semaglutide.
• Survodutide (Boehringer Ingelheim) — dual GLP-1/glucagon agonist.

How to Choose Between Them

Most patients have two main decisions:

1. Semaglutide vs tirzepatide. Tirzepatide produces larger weight loss on average but is somewhat newer. Semaglutide has a longer safety record and more cardiovascular outcomes data.
2. Brand vs compounded. Brand carries FDA manufacturing oversight; compounded is significantly cheaper. See compounded semaglutide and compounded tirzepatide.

A telehealth or in-person provider will help you weigh side-effect history, insurance coverage, cost preference, and goals.

Related Reading

• Semaglutide · Tirzepatide
• Best GLP-1 for Weight Loss
• Cost Comparison
• How to Get Online

Sources

• FDA prescribing information for all listed drugs.
• STEP, SURMOUNT, SURPASS, SUSTAIN, REWIND, LEADER clinical trial publications.